Peptides that bind to HSP90 proteins

Details Peptides that bind to HSP90 proteins Peptides that bind to HSP90 proteins

2005-01-12

2009-02-17

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S012200, C514S013800, C514S015800, C514S016700, C530S300000, C530S324000, C530S325000, C530S326000, C530S327000, C530S328000, C530S329000

Reexamination Certificate

active

07491701

ABSTRACT:
YSLPGYMVKKLLGA (SEQ ID NO:1) and its active analogs, compositions, and methods of use.

REFERENCES:
patent: 3595955 (1971-07-01), De Boer et al.
patent: 4261989 (1981-04-01), Sasaki et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 5387584 (1995-02-01), Schnur
patent: 5519116 (1996-05-01), Wagner et al.
patent: 5595887 (1997-01-01), Coolidge et al.
patent: 5932566 (1999-08-01), Schnur et al.
patent: 6245759 (2001-06-01), Bilodeau et al.
patent: 6306874 (2001-10-01), Fraley et al.
patent: 6313138 (2001-11-01), Fraley et al.
patent: 2003/0194409 (2003-10-01), Rothman et al.
patent: WO01/70972 (2001-09-01), None
patent: WO 2005/072766 (2005-08-01), None
patent: WO 2005/072766 (2005-08-01), None
Protein Purification Handbook, Amersham Biosciences, Edition AC, 2001.
Andersson et al., “Protein Targeting to Endoplasmic Reticulum by Dilysine Signals Involves Direct Retention in Addition to Retrieval”,Journal of Biol. Chem., 1999; 274:15080-15084.
Bansal et al., “Dysferlin and the plasma membrane repair in muscular dystrophy,”Trends in Cell Biology, Apr. 2004; 14(4):206-213.
Bi et al., “Calcium-regulated Exocytosis is Required for Cell Membrance Resealing,”Journal of Cell Biol., Dec. 1995; 131(6):1747-1758.
Bosch et al., “Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective,”Journal of the National Cancer Institute, Jun. 1995; 87(11):796-802.
Buchner, “Hsp90 & Co.—a holding for folding,”TIBS, Apr. 1999; 24:136-141.
Bushby, “Dysferlin and muscular dystrophy,”Acta Neurol. Belg., 2002; 100:142-145.
Caplan, “Hsp90's secrets unfold: new insights from structural and functional studies,”Trends in Cell. Biol., Jul. 1999; 9:262-268.
Chang et al., “Hsc70 is required for endocytosis and clathrin function inDrosphila,” J. Cell. Biol., 2002; 159(3):477-487.
Chen et al., “Hypoxia increases Hsp90 binding to eNOS via P13K-Akt in porcine coronary artery endothelium,”Lab. Invest., 2004; 84:182-190.
Citri et al., “Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy,”EMBO Journal, 2002; 21(10):2407-2417.
Dai et al., “Physical Interaction of Mammalian CDC37 with CDK4,”J. Biol. Chem., 1996; 271:22030-22034.
Detrait et al., “Axolemmal Repair Requires Proteins That Mediate Synaptic Vesicle Fusion,”J. Neurobiol., 2000; 44:382-391.
Draper et al., “Use of Aminoglycoside Antibiotics and Related Compounds to Study ADP-Riboslation Factor (ARF)/Coatomer Function in Golgi Traffic”,Methods in Enzymology, 2001; 329:372-379.
Dyson, “The regulation of E2F by pRB-family proteins,”Genes Dev., 1998; 12:2245-2262.
Egan et al., “Binding of theRb1protein to E1A products is required for adenovirus transformation,”Oncogene, 1989; 4:383-388.
Goldberg, “Decoding of sorting signals by Coatomer through a GTPase Switch in the COPI Coat Complex”,Cell., Mar. 17, 2000; 100(6):671-679.
Grenert et al., “The Amino-terminal Domain of Heat Shock Protein 90 (hsp90) That Binds Geldanamycin Is an ATP/ADP Switch Domain That Regulates hsp90 Conformation,”J. Biol. Chem., 1997; 272(38):23843-23850.
Hartmann et al., “Effects of the Tyrosine-Kinase Inhibitor Geldanamycin on Ligand-Induced HER-2/NEU Activation, Receptor Expression and Proliferation of HER-2-Positive Malignant Cell Lines,”Int. J. Cancer, 1997; 70:221-229.
Higashiyama et al., “Retinoblastoma Protein Expression in Lung Cancer: An Immunohistochemical Analysis,”Oncology, 1994; 51:544-551.
Hudson et al., “Interaction of coatomer with aminoglycoside antibiotics; evidence that coatomer has at least two dilysine binding sites”,Mol. Biol. Cell, Oct. 8, 1997; 8(10):1901-10.
Hu et al., “Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase,”Proc Natl Acad Sci USA, Feb. 1996; 93:1060-1064.
Ishiji, “Molecular Mechanism of Carcinogenesis by Human Papillomavirus-16,”J. Dermatol., 2000; 27:73-86.
Kamal et al., “A high-affinity conformation of Hsp90 cofers tumour selectivity on Hsp90 inhibitors”,Nature, Sep. 25, 2003; 425(6956):407-410.
Kohn et al., “Colonic retinoblastoma protein and proliferation in cancer and non-cancer patients,”J. Gasroenterol. Hepatol., Mar. 1997; 12(3):198-203: http://gateway.ut.ovid.com/gw1/ovidweb.cgi (Apr. 29, 2005).
Kuhn-Nentwig, “Antimicrobial and cytolytic peptides of venomous arthropods”,Cell. Mol. Life Sci., 2003; 60:2651-2688.
Letourneur et al., “Coatomer is Essential for Retrieval of Dilysine-Tagged Proteins to the Endoplasmic Reticulum,”Cell, Dec. 1994; 79:1199-1207.
Letunic et al., “Recent improvements to the SMART domain-based sequence annotation resource,”Nucleic Acids Res., 2002; 30(1):242-244.
Maloney et al., “HSP90 as a new therapeutic target for cancer therapy: the story unfolds,”Expert Opin. Biol. Ther., 2002; 2(1):3-24.
Mayorga et al., “Calcium-dependent Fusion Among Endosomes,”J. Biol. Chem., Dec. 1994; 269(49):30927-30934.
Miller et al., “Depletion of theerbB-2 Gene Product p185 by Benzoquinoid Ansamycins,”Cancer Res., May 1994; 54:2724-2730.
Mimnaugh et al., “Polyubiquitination and Proteasomal Degradation of the p185c-erbB-2Receptor Protein-tyrosine Kinase Induced by Geldanamycin,”J. Biol. Chem., Sep. 1996; 271(37):22796-22801.
Miyake et al., “Vesicle Accumulation and Exocytosis at Sites of Plasma Membrane Disruption,”J. Cell. Biol., 1996; 131(6):1737-1745.
Muise-Helmericks et al., “Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway,”J. Biol. Chem., Nov. 1998; 273(45):29864-29872.
Munster, “Modulation of Hsp90 Function by Ansamycins Sensitizes Breast Cancer Cells to Chemotherapy-induced Apoptosis in an RB-and Schedule-dependent Manner,”Clinical Cancer Research, Aug. 2001; 7:2228-2236.
Neckers, “Development of Small Molecule Hsp90 Inhibitors: Utilizing Both Forward and Reverse Chemical Genomics for Drug Identification,”Cur. Med. Chem.2003; 10:733-739.
Newmyer et al., “Dominant-interfering Hsc70 Mutants Disrupt Multiple Stages of the Clathrin-coated Vesicle Cycle In Vivo,”J. Cell. Biol., 2001; 152(3):607-620.
Panaretou et al., “ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo,”EMBO J., 17(16):4829-4836.
Pratt et al., “Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery,”Soc. for Exp. Biol. Med., 2003; 228:111-133.
Presti et al., “Expression of the Retinoblastoma Gene Product in Renal Tumors,”Anticancer Res., 1996; 16:549-556.
Prodromou et al., “Identification and Structural Characterization of the ATP/ADP-Binding Site in the Hsp90 Molecular Chaperone,”Cell, 1997; 90;65-75.
Rygaard et al., “Abnormalities in Structure and Expression of the Retinoblastoma Gene in Small Cell Lung Cancer Cell Lines and Xenografts in Nude Mice,”Cancer Res., Sep. 1990; 50:5312-5317.
Ryo et al., “Prolyl isomerase Pin 1: a catalyst for oncogenesis and a potential therapeutic target in cancer,”J Cell Sci., 2003; 116:773-783.
Sasagawa et al., “Serological Responses to Human Papillomavirus Type 6 and 16 Virus-Like Particles in Patients with Cervical Neoplastic Lesions,”Clinical Diag. Lab. Immunol, 1996; 3(4):403-410.
Scheffner et al., “The E6 Oncoprotein Encoded by Human Papillomavirus Types 16 and 18 Promotes the Degradation of p53,”Cell, Dec. 1990, 63:1129-1136.
Scheibel et al., “The charged region of Hsp90 modulates the function of the N-terminal domain,”Proc. Natl. Acad. Sci. USA, 1999; 96:1297-1302.
Schneider et al., “Pharmacologic shifting of a balance between protein

Affiliated with

Also associated with

Rating

Peptides that bind to HSP90 proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides that bind to HSP90 proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides that bind to HSP90 proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4119833